Silexion Therapeutics Corp (NASDAQ:SLXN) announces breakthrough preclinical results for SIL204, a next-gen RNAi therapy showing potent anti-tumor effects in KRAS-driven cancers.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Silexion Therapeutics Corp (SLXN)'s RNAi Therapy Blocks 90% of Colorectal Tumors
